First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

First comprehensive tool for screening pain in Parkinson's disease : the King's Parkinson's Disease Pain Questionnaire. / Martinez-Martin, P.; Rizos, A. M.; Wetmore, J.; Antonini, A.; Odin, P.; Pal, S.; Sophia, R.; Carroll, C.; Martino, D.; Falup-Pecurariu, C.; Kessel, B.; Andrews, T.; Paviour, D.; Trenkwalder, C.; Chaudhuri, K. R.; EUROPAR ; MDS Non-motor PD Study Group.

I: European Journal of Neurology, Vol. 25, Nr. 10, 2018, s. 1255-1261.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Martinez-Martin, P, Rizos, AM, Wetmore, J, Antonini, A, Odin, P, Pal, S, Sophia, R, Carroll, C, Martino, D, Falup-Pecurariu, C, Kessel, B, Andrews, T, Paviour, D, Trenkwalder, C, Chaudhuri, KR, EUROPAR & MDS Non-motor PD Study Group 2018, 'First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire', European Journal of Neurology, vol. 25, nr. 10, s. 1255-1261. https://doi.org/10.1111/ene.13691

APA

Martinez-Martin, P., Rizos, A. M., Wetmore, J., Antonini, A., Odin, P., Pal, S., Sophia, R., Carroll, C., Martino, D., Falup-Pecurariu, C., Kessel, B., Andrews, T., Paviour, D., Trenkwalder, C., Chaudhuri, K. R., EUROPAR , & MDS Non-motor PD Study Group (2018). First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. European Journal of Neurology, 25(10), 1255-1261. https://doi.org/10.1111/ene.13691

CBE

Martinez-Martin P, Rizos AM, Wetmore J, Antonini A, Odin P, Pal S, Sophia R, Carroll C, Martino D, Falup-Pecurariu C, Kessel B, Andrews T, Paviour D, Trenkwalder C, Chaudhuri KR, EUROPAR , MDS Non-motor PD Study Group. 2018. First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. European Journal of Neurology. 25(10):1255-1261. https://doi.org/10.1111/ene.13691

MLA

Vancouver

Author

Martinez-Martin, P. ; Rizos, A. M. ; Wetmore, J. ; Antonini, A. ; Odin, P. ; Pal, S. ; Sophia, R. ; Carroll, C. ; Martino, D. ; Falup-Pecurariu, C. ; Kessel, B. ; Andrews, T. ; Paviour, D. ; Trenkwalder, C. ; Chaudhuri, K. R. ; EUROPAR ; MDS Non-motor PD Study Group. / First comprehensive tool for screening pain in Parkinson's disease : the King's Parkinson's Disease Pain Questionnaire. I: European Journal of Neurology. 2018 ; Vol. 25, Nr. 10. s. 1255-1261.

RIS

TY - JOUR

T1 - First comprehensive tool for screening pain in Parkinson's disease

T2 - the King's Parkinson's Disease Pain Questionnaire

AU - Martinez-Martin, P.

AU - Rizos, A. M.

AU - Wetmore, J.

AU - Antonini, A.

AU - Odin, P.

AU - Pal, S.

AU - Sophia, R.

AU - Carroll, C.

AU - Martino, D.

AU - Falup-Pecurariu, C.

AU - Kessel, B.

AU - Andrews, T.

AU - Paviour, D.

AU - Trenkwalder, C.

AU - Chaudhuri, K. R.

AU - EUROPAR

AU - MDS Non-motor PD Study Group

PY - 2018

Y1 - 2018

N2 - Background and purpose: Pain is highly prevalent in Parkinson's disease (PD), impacting patients’ ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test–retest) and diagnostic performance of the questionnaire were analysed. Results: Data from 300 patients and 150 controls are reported. PD patients declared significantly more pain symptoms than controls (3.96 ± 2.56 vs. 2.17 ± 1.39; P < 0.0001). The KPPQ convergent validity was high with KPPS total score (rS = 0.80) but weak or moderate with other pain assessments. Test–retest reliability was satisfactory with kappa values ≥0.65 except for item 5, Dyskinetic pains (κ = 0.44), and the intraclass correlation coefficient (ICC) for the KPPQ total score was 0.98. After the scores of the KPPS were adapted for screening (0, no symptom; ≥1, symptom present), a good agreement was found between the KPPQ and the KPPS (ICC = 0.88). A strong correlation (rS = 0.80) between the two instruments was found. The diagnostic parameters of the KPPQ were very satisfactory as a whole, with a global accuracy of 78.3%–98.3%. Conclusions: These results suggest that the KPPQ is a useful, reliable and valid screening instrument for pain in PD to advance patient-related outcomes.

AB - Background and purpose: Pain is highly prevalent in Parkinson's disease (PD), impacting patients’ ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test–retest) and diagnostic performance of the questionnaire were analysed. Results: Data from 300 patients and 150 controls are reported. PD patients declared significantly more pain symptoms than controls (3.96 ± 2.56 vs. 2.17 ± 1.39; P < 0.0001). The KPPQ convergent validity was high with KPPS total score (rS = 0.80) but weak or moderate with other pain assessments. Test–retest reliability was satisfactory with kappa values ≥0.65 except for item 5, Dyskinetic pains (κ = 0.44), and the intraclass correlation coefficient (ICC) for the KPPQ total score was 0.98. After the scores of the KPPS were adapted for screening (0, no symptom; ≥1, symptom present), a good agreement was found between the KPPQ and the KPPS (ICC = 0.88). A strong correlation (rS = 0.80) between the two instruments was found. The diagnostic parameters of the KPPQ were very satisfactory as a whole, with a global accuracy of 78.3%–98.3%. Conclusions: These results suggest that the KPPQ is a useful, reliable and valid screening instrument for pain in PD to advance patient-related outcomes.

KW - assessment

KW - King's Parkinson's Disease Pain Questionnaire

KW - pain

KW - Parkinson's disease

KW - screening

KW - validation

U2 - 10.1111/ene.13691

DO - 10.1111/ene.13691

M3 - Article

C2 - 29806962

AN - SCOPUS:85053007934

VL - 25

SP - 1255

EP - 1261

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 10

ER -